HRT, Mood, and Depression: Why They Travel Together and How Treatment Decisions Get Made

Mood symptoms in midlife are one of the most undertreated and misdiagnosed clusters in women’s healthcare. Anxiety that feels new and unexplained, irritability that surprises the woman experiencing it, low mood that does not respond to circumstances, and rage episodes that feel out of character all show up during the perimenopausal transition for reasons rooted in brain chemistry. Yet these symptoms are often treated as primary mood disorders with antidepressants alone, missing the hormonal driver that makes them treatable through a different route. This guide explains why HRT, mood, and depression travel together, what the evidence shows about hormone therapy as a mood intervention, and when antidepressants, HRT, or both are appropriate.

HRT, Mood, and Depression: How Estrogen Affects Brain Chemistry

Estrogen is not a peripheral reproductive hormone. It is a neuroactive molecule with receptors throughout the brain, particularly in regions involved in mood regulation, including the prefrontal cortex, the hippocampus, the amygdala, and the limbic system. Estrogen modulates the production, release, and receptor sensitivity of serotonin, dopamine, and norepinephrine, the same neurotransmitters targeted by most antidepressant medications. When estrogen fluctuates wildly during perimenopause and then declines into menopause, those neurotransmitter systems are directly affected, producing the mood symptoms women describe.

Progesterone has its own brain chemistry effects through a different mechanism. Progesterone metabolizes to allopregnanolone, which activates GABA-A receptors, the same receptor system targeted by benzodiazepines and alcohol. This produces anxiolytic and sedating effects that contribute to the calming influence of progesterone in the body. When progesterone declines in early perimenopause, often before any obvious cycle changes appear, anxiety and sleep disruption frequently emerge as some of the earliest symptoms. Testosterone also contributes, modulating dopamine pathways involved in motivation, drive, and reward processing.

The HRT Mood Depression Connection in Practice

The clinical implication of this brain chemistry is direct: many of the mood symptoms women experience in midlife are not freestanding mood disorders. They are downstream effects of hormonal change, and they often respond to addressing the hormonal driver in ways that pure antidepressant treatment alone does not match. This is the reason the HRT mood depression conversation has shifted significantly over the past decade, with hormone therapy increasingly recognized as a legitimate first-line consideration for perimenopausal-onset mood symptoms.

Perimenopausal Depression vs Classical Depression

Perimenopausal depression has clinical features that often distinguish it from classical major depressive disorder. The onset typically occurs in the late 30s to mid-40s, frequently in women without prior psychiatric history. Mood symptoms often follow a cyclical pattern, worse in the days before menstrual periods and somewhat improved after periods begin. Anxiety, irritability, and rage are often more prominent than the persistent flat mood of classical depression. Sleep disruption is severe and is the kind that responds to progesterone. Cognitive symptoms (brain fog, word-finding difficulty) travel with the mood symptoms, suggesting a shared mechanism. For the cyclical version, where symptoms clear once bleeding starts, see our guide to PMDD and perimenopause.

This pattern, often called perimenopausal-onset depression in the literature, is increasingly recognized as a distinct clinical entity. The Harvard Study of Moods and Cycles by Cohen and colleagues, published in Archives of General Psychiatry, demonstrated that women in the menopausal transition had a substantially higher risk of new-onset depression than premenopausal women, and that the risk was associated with the hormonal changes of the transition rather than with life stress alone. Treating this presentation as standard major depression with an SSRI alone often produces partial response at best, because the hormonal driver remains unaddressed.

What the Evidence Shows for HRT and Mood

Multiple studies have examined whether HRT improves mood in perimenopausal and menopausal women, and the general direction of findings is favorable. Estradiol therapy has shown antidepressant effects in perimenopausal women in several randomized trials, including Soares and colleagues in Archives of General Psychiatry, where transdermal estradiol produced significantly greater mood improvement than placebo in perimenopausal depressed women. The effect sizes are clinically meaningful, comparable in magnitude to standard antidepressant therapy in this specific population.

For postmenopausal women, the picture is more mixed. HRT shows mood benefit in many women, but the effect tends to be less dramatic than in perimenopausal women, possibly because the hormonal volatility of perimenopause is the strongest driver of mood symptoms. Once a woman is fully postmenopausal with stably low hormones, mood symptoms may have other contributors that HRT alone cannot fully address. The 2022 NAMS position statement, available at the Menopause Society NAMS HRT position statement page, recognizes mood symptoms as a legitimate indication for HRT consideration in symptomatic perimenopausal women.

The WHI studied oral conjugated equine estrogen plus medroxyprogesterone acetate, not the modern formulation of transdermal estradiol plus micronized progesterone used today, and the WHI was not designed primarily to evaluate mood outcomes. The mood-relevant evidence on modern HRT formulations comes largely from subsequent studies in narrower populations and observational data.

When Both HRT and Antidepressants Are Appropriate

Some women clearly need both interventions. The decision is not “HRT vs antidepressant” but “HRT plus antidepressant when both are indicated.” Specific situations where combination treatment is often appropriate include women with established major depression that predates perimenopause but has worsened during the transition, women with perimenopausal depression that has not fully responded to HRT alone, women with significant anxiety or panic that requires more than progesterone’s GABA effects, and women whose suicidality or severe symptoms warrant aggressive treatment from multiple angles.

Combining HRT and antidepressants is generally well-tolerated. There are no major drug interactions between SSRIs or SNRIs and bioidentical estradiol or micronized progesterone. The combination often produces better mood outcomes than either intervention alone for women whose symptoms have both a hormonal and a non-hormonal driver. Once both treatments are working, some women can taper one or the other over time, though many find the combination optimal long-term.

The Role of Testosterone in Mood Symptoms

Testosterone is often overlooked in the mood conversation but contributes meaningfully in some women. The mood pattern most associated with low female testosterone is emotional flatness, reduced motivation, low enthusiasm, and a sense of being disengaged from life. This is different from the sad, anxious, or irritable presentations driven by estradiol and progesterone fluctuations. Women whose mood improves on estradiol and progesterone but who still report this kind of flat, low-drive mood often benefit from low-dose testosterone replacement.

The combination of estradiol, micronized progesterone, and low-dose testosterone in women with the appropriate symptom and lab picture sometimes produces mood outcomes that no single hormone could match. For more on the testosterone component, see our guide on testosterone for women.

When HRT Is Not Enough for Mood Symptoms

Several situations call for adding non-hormonal treatment beyond HRT. Persistent mood symptoms after 12 weeks on appropriately dosed HRT suggest the mood disorder has its own driver that hormones alone will not address. Severe symptoms with functional impairment (inability to work, severe insomnia, suicidality) warrant immediate antidepressant or specialist consultation alongside hormone optimization. Pre-existing major depression with worsening during perimenopause often needs both treatments concurrently. Mood symptoms that emerged before any clear hormonal changes, in early-30s women without other perimenopausal indicators, may have a different underlying cause that needs evaluation.

Current evidence supports initiating HRT within 10 years of the menopausal transition, or before age 60, for the most favorable benefit-to-risk profile, and the mood benefits of HRT are typically captured during this window. Women older than this who have established mood disorders may still benefit from individualized HRT consideration but typically receive less dramatic mood improvement than women treated during the perimenopausal transition.

What to Discuss With Your Clinician

An informed conversation about HRT and mood begins with naming the mood symptoms specifically. “I am irritable” carries different clinical implications than “I have lost interest in things I used to enjoy” or “I wake at 3 a.m. with anxiety.” The cyclical pattern (better or worse with menstrual cycles) is also informative; cyclical mood symptoms strongly suggest a hormonal driver, while non-cyclical persistent flat mood may have a different mechanism. The history of prior mood disorders matters, as does the family history. Sleep quality affects everything and deserves separate attention. Thyroid function, B12 status, and iron status are commonly missed contributors to mood symptoms in midlife women.

A responsible HRT consultation for mood symptoms includes a full hormone panel, thyroid panel, metabolic markers, and screening for non-hormonal contributors. The decision about whether to use HRT, antidepressants, both, or neither is made based on this full picture rather than on any single symptom or lab value.

The Bottom Line

HRT, mood, and depression are connected through brain chemistry, not coincidence. Estrogen, progesterone, and testosterone all directly modulate the systems involved in mood regulation, and their fluctuation in perimenopause produces the cluster of mood symptoms many women experience. For perimenopausal-onset mood symptoms, HRT often produces meaningful improvement and may be more appropriate than an SSRI alone. For established major depression that worsens in perimenopause, both HRT and antidepressants often work best together. The right treatment is individualized and depends on the symptom picture, hormonal status, and overall clinical context, not on a one-size-fits-all answer.

Medically Reviewed By

Dr. Ashar N., DNP, APRN, FNP-C, PMHNP-BC

Co-Founder & Medical Director at Tactus Health. Dual board-certified, with clinical focus on hormone therapy, medical weight loss, and aesthetics. Sugar Hill, GA and telehealth for Georgia patients.